Publicacións (25) Publicacións de JOSE LUIS LABANDEIRA GARCIA Ver datos de investigación referenciados.

filter_list Neurology

2021

  1. Glucocerebrosidase gene therapy induces alpha-synuclein clearance and neuroprotection of midbrain dopaminergic neurons in mice and macaques

    International Journal of Molecular Sciences, Vol. 22, Núm. 9

  2. Novel Interactions Involving the Mas Receptor Show Potential of the Renin–Angiotensin system in the Regulation of Microglia Activation: Altered Expression in Parkinsonism and Dyskinesia

    Neurotherapeutics, Vol. 18, Núm. 2, pp. 998-1016

2020

  1. Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA

    Frontiers in Neuroanatomy, Vol. 14

  2. Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease

    British Journal of Pharmacology, Vol. 177, Núm. 24, pp. 5622-5641

2018

  1. Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death

    Neurotherapeutics, Vol. 15, Núm. 4, pp. 1063-1081

  2. Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson’s Disease Models

    Molecular Neurobiology, Vol. 55, Núm. 9, pp. 7297-7316

2017

  1. Brain renin-angiotensin system and microglial polarization: Implications for aging and neurodegeneration

    Frontiers in Aging Neuroscience, Vol. 9, Núm. MAY

2016

  1. Chronic and progressive Parkinson's disease MPTP model in adult and aged mice

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 373-387

2015

  1. Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinsons Disease

    Neuroscientist, Vol. 21, Núm. 6, pp. 616-629

2014

  1. Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β

    Experimental Neurology, Vol. 261, pp. 720-732

  2. Brain renin-angiotensin system and dopaminergic cell vulnerability

    Frontiers in Neuroanatomy, Vol. 8, Núm. JULY

  3. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA

    Neuropharmacology, Vol. 76, Núm. PART A, pp. 156-168

  4. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death

    Neuropharmacology, Vol. 85, pp. 1-8

  5. Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin

    GLIA, Vol. 62, Núm. 1, pp. 145-157

2013

  1. Dopamine-Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease

    Movement Disorders, Vol. 28, Núm. 10, pp. 1337-1342

2012

  1. Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors

    Neurobiology of Disease, Vol. 47, Núm. 2, pp. 268-279

2010

  1. Location of prorenin receptors in primate substantia nigra: Effects on dopaminergic cell death

    Journal of Neuropathology and Experimental Neurology, Vol. 69, Núm. 11, pp. 1130-1142

2008

  1. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS

    Neurobiology of Disease, Vol. 31, Núm. 1, pp. 58-73

2007

  1. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons

    Neurobiology of Aging, Vol. 28, Núm. 4, pp. 555-567

2005

  1. Angiotensin II and interleukin-1 interact to increase generation of dopaminergic neurons from neurospheres of mesencephalic precursors

    Developmental Brain Research, Vol. 158, Núm. 1-2, pp. 120-122